Liraglutide Research for Obesity
An evidence-based overview of research examining Liraglutide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Saxenda is FDA-approved for long-term weight reduction in adults with obesity or overweight plus a weight-related comorbidity, and in youths aged 12 years or older with obesity and body weight above 60 kg. In the cited adult SCALE trial, mean body-weight reduction was about 8% at 56 weeks and 63% achieved at least 5% weight reduction. A separate adolescent trial supports the labeled age-12-and-older obesity indication; adult SCALE percentages should not be transferred to that population.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.